Showing 4891-4900 of 5623 results for "".
- Clearside Biomedical Revises NDA Resubmission Timeline and Xipere Commercial Partnership with Bausch Healthhttps://modernod.com/news/clearside-biomedical-revises-nda-resubmission-timeline-and-xipere-commercial-partnership-with-bausch-health/2477660/Clearside Biomedical announced an update to the Xipere (triamcinolone acetonide suprachoroidal injectable suspension) new drug application (NDA) resubmission timeline and to its commercialization and development partnership with Bausch Health Companies and Bausch + Lomb.
- New Dates Announced for BMC Virtual Spring Symposiumhttps://modernod.com/news/new-dates-announced-for-bmc-virtual-spring-symposium/2477658/Bryn Mawr Communications (BMC) has announced that its first virtual educational initiative, the BMC Virtual Spring Symposium, will now be held on May 29-30. The BMC Virtual Spring Symposium is designed to enable discussion, engagement, and live Q&A for members of the vision community w
- I-MED Pharma Gains Health Canada Approval For E>Eye Laserhttps://modernod.com/news/i-med-pharma-gains-health-canada-approval-for-eeye-laser/2477656/I-MED Pharma has announced Health Canada approval for dry eye device E>Eye Laser, which is now available to Canadian eye care professionals. E>Eye, designed and manufactured in France by E-Swin, is the only CE certified medical device using patented IRPL technology developed specifi
- David Rostov Joins CorneaGen as Chief Financial Officerhttps://modernod.com/news/david-rostov-joins-corneagen-as-chief-financial-officer/2477648/CorneaGen announced that David Rostov has joined the company as chief financial officer. Mr. Rostov has more than 20 years of C-suite experience in scaling fast-growing technology companies, mergers and acquisitions and corpor
- COVID-19 Vaccine Protects Monkeys From New Coronavirus, Chinese Biotech Reportshttps://modernod.com/news/covid-19-vaccine-protects-monkeys-from-new-coronavirus-chinese-biotech-reports/2477646/For the first time, one of the many COVID-19 vaccines in development has protected an animal, rhesus macaques, from infection by the new coronavirus, according to a
- Ambulatory Surgery Centers Eligible For New Relief Grant Fundshttps://modernod.com/news/ambulatory-surgery-centers-eligible-for-new-relief-grant-funds-on-april-24/2477642/The Department of Health and Human Services (HHS) announced that, commencing April 24, health care providers, including ASCs, will be eligible to receive grants from a newly available pool of COVID-19 relief funds, according to The Outpatient Ophthalmic Surgery Society (OOSS). These grants are a
- Lancet Neurology Publishes Pivotal Phase 3 Data for Genentech’s Satralizumab for NMOSDhttps://modernod.com/news/lancet-neurology-publishes-pivotal-phase-3-data-for-genentechs-satralizumab-for-nmosd/2477640/Lancet Neurology published full pivotal phase 3 clinical data on investigational medicine satralizumab as a monotherapy for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system disease that is commonly misdiagnosed as multiple scler
- Johnson & Johnson Vision Appoints Rajesh K. Rajpal, MD, Chief Medical Officerhttps://modernod.com/news/johnson-johnson-vision-appoints-rajesh-k-rajpal-md-chief-medical-officer/2477634/Johnson & Johnson Vision has appointed Rajesh K. Rajpal, MD, as Chief Medical Officer and Global Head of Clinical and Medical Affairs. In this role, Dr. Rajpal will lead the integration of rapidly evolving medical and clinical insights into new product development to address unmet needs of pa
- Regenxbio Announces Additional Positive Long-Term and Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-long-term-and-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd/2477630/Regenxbio provided additional long-term data from the ongoing phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). In the phase 1/2a trial of RGX-314, 42 patients with severe wet AMD requiring frequent anti-vascular endothelial growth factor (anti-VE
- Novartis Acquires Amblyotech, A Provider of Digital Therapy for Treatment of Amblyopiahttps://modernod.com/news/novartis-acquires-amblyotech-a-provider-of-digital-therapy-for-treatment-of-amblyopia/2477623/Novartis announced that it has completed the acquisition of Amblyotech, a US-based software startup, and will, in collaboration with Ubisoft and McGill University, pursue the development of the acquired digital technology for the treatment of amblyopia. It is estimated that amblyopia affec